MET and hepatocellular carcinoma: It has been demonstrated that small EVs released from invasive hepatocellular carcinoma (HCC) cell lines promote sorafenib resistance in hepatoma cells in vitro through the activation of the HGF/c-Met/Akt signaling pathway and through the inhibition of sorafenib-mediated apoptosis; moreover, authors showed that resistance was not only observed in vitro, but also in vivo [71].